Results 131 to 140 of about 59,390 (261)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Assessing the Effectiveness of the Human Immunodeficiency Virus Point-of-Care Proficiency Testing Scheme: Analysis of the Data From 2021 to 2022 in South Africa. [PDF]

Health Sci Rep
Blasich NP, Adelekan AM.
europepmc   +1 more source

Utilizing proficiency testing survey data to create advanced educational content: the virtual crossmatch challenge model. [PDF]

Front Genet, 2023
Hod-Dvorai R, Philogene MC, Timofeeva O, Gimferrer I, Dunckley H, Greenshields A, Jindra P.   +6 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Editorial: Proficiency testing in histocompatibility and immunogenetics: current status and future perspectives. [PDF]

Front Genet
Petrek M, Hitchman KMK.
europepmc   +1 more source

Busulfan Interlaboratory Proficiency Testing Program Revealed Worldwide Errors in Drug Quantitation and Dose Recommendations. [PDF]

Ther Drug Monit, 2023
Kweekel DM, McCune JS, Punt AM, van Luin M, Franssen EJF.   +4 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Five-Year Experience of the Groupe de Recherche Action en Santé (GRAS) Clinical Laboratory, Burkina Faso, in Participating into an External Proficiency Testing (EPT) Programme. [PDF]

Diagnostics (Basel)
Diarra A, Nébié I, Henry NB, Ouédraogo A, Konaté AT, Tiono AB, Sirima SB.   +6 more
europepmc   +1 more source

Longitudinal Evaluation of AFP and CEA External Proficiency Testing Reveals Need for Method Harmonization. [PDF]

Diagnostics (Basel), 2023
Wojtalewicz N, Vierbaum L, Kaufmann A, Schellenberg I, Holdenrieder S.   +4 more
europepmc   +1 more source